260 related articles for article (PubMed ID: 16061391)
1. Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma.
Campo S; Serlupi-Crescenzi O; Arseni B; Rossi S; Saggio I; Salone B; Cherubini G; Carminati P; De Santis R
Cytokine; 2005 Sep; 31(5):368-74. PubMed ID: 16061391
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
3. Pathogenic role of interleukin-6 in the development of sepsis. Part II: Significance of anti-interleukin-6 and anti-soluble interleukin-6 receptor-alpha antibodies in a standardized murine contact burn model.
Pallua N; Low JF; von Heimburg D
Crit Care Med; 2003 May; 31(5):1495-501. PubMed ID: 12771624
[TBL] [Abstract][Full Text] [Related]
4. Human interleukin-6 is in vivo an autocrine growth factor for human herpesvirus-8-infected malignant B lymphocytes.
Foussat A; Wijdenes J; Bouchet L; Gaidano G; Neipel F; Balabanian K; Galanaud P; Couderc J; Emilie D
Eur Cytokine Netw; 1999 Dec; 10(4):501-8. PubMed ID: 10586116
[TBL] [Abstract][Full Text] [Related]
5. Local blockade of IL-6R signaling induces lung CD4+ T cell apoptosis in a murine model of asthma via regulatory T cells.
Finotto S; Eigenbrod T; Karwot R; Boross I; Doganci A; Ito H; Nishimoto N; Yoshizaki K; Kishimoto T; Rose-John S; Galle PR; Neurath MF
Int Immunol; 2007 Jun; 19(6):685-93. PubMed ID: 17496315
[TBL] [Abstract][Full Text] [Related]
6. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody.
Mizutani Y; Bonavida B; Koishihara Y; Akamatsu K; Ohsugi Y; Yoshida O
Cancer Res; 1995 Feb; 55(3):590-6. PubMed ID: 7834629
[TBL] [Abstract][Full Text] [Related]
7. Limited involvement of interleukin-6 in the pathogenesis of lethal septic shock as revealed by the effect of monoclonal antibodies against interleukin-6 or its receptor in various murine models.
Libert C; Vink A; Coulie P; Brouckaert P; Everaerdt B; Van Snick J; Fiers W
Eur J Immunol; 1992 Oct; 22(10):2625-30. PubMed ID: 1327800
[TBL] [Abstract][Full Text] [Related]
8. Development of a monoclonal antibody-based enzyme-linked immunoabsorbent assay for the binding of gp130 to the IL-6/IL-6R complex and its competitive inhibition.
Scheller J; Kovaleva M; Rabe B; Eichler J; Kallen KJ; Rose-John S
J Immunol Methods; 2004 Aug; 291(1-2):93-100. PubMed ID: 15345308
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD45 and anti-CD52 (Campath) monoclonal antibodies effectively eliminate systematically disseminated human non-Hodgkin's lymphoma B cells in Scid mice.
de Kroon JF; de Paus RA; Kluin-Nelemans HC; Kluin PM; van Bergen CA; Munro AJ; Hale G; Willemze R; Falkenburg JH
Exp Hematol; 1996 Jul; 24(8):919-26. PubMed ID: 8690051
[TBL] [Abstract][Full Text] [Related]
10. Soluble interleukin 6 receptor is biologically active in vivo.
Mackiewicz A; Wiznerowicz M; Roeb E; Karczewska A; Nowak J; Heinrich PC; Rose-John S
Cytokine; 1995 Feb; 7(2):142-9. PubMed ID: 7780033
[TBL] [Abstract][Full Text] [Related]
11. Optimizing therapeutic strategies to inhibit circulating soluble target molecules with monoclonal antibodies: example of the soluble IL-6 receptors.
Brochier J; Liautard J; Jacquet C; Gaillard JP; Klein B
Eur J Immunol; 2001 Jan; 31(1):259-64. PubMed ID: 11265642
[TBL] [Abstract][Full Text] [Related]
12. Establishment of the ELISA for murine soluble gp130, a signal transducer for the IL-6 family cytokine, and its detection in the ascitic fluids of tumor-bearing mice.
Matsuda T; Hirano T
Biochem Biophys Res Commun; 1994 Jul; 202(1):637-42. PubMed ID: 8037770
[TBL] [Abstract][Full Text] [Related]
13. Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo.
Suzuki H; Yasukawa K; Saito T; Goitsuka R; Hasegawa A; Ohsugi Y; Taga T; Kishimoto T
Eur J Immunol; 1992 Aug; 22(8):1989-93. PubMed ID: 1639101
[TBL] [Abstract][Full Text] [Related]
14. Treatment of rheumatoid synovitis with anti-reshaping human interleukin-6 receptor monoclonal antibody: use of rheumatoid arthritis tissue implants in the SCID mouse model.
Matsuno H; Sawai T; Nezuka T; Uzuki M; Tsuji H; Nishimoto N; Yoshizaki K
Arthritis Rheum; 1998 Nov; 41(11):2014-21. PubMed ID: 9811057
[TBL] [Abstract][Full Text] [Related]
15. A combination of interleukin-6 and its soluble receptor impairs sperm motility: implications in infertility associated with endometriosis.
Yoshida S; Harada T; Iwabe T; Taniguchi F; Mitsunari M; Yamauchi N; Deura I; Horie S; Terakawa N
Hum Reprod; 2004 Aug; 19(8):1821-5. PubMed ID: 15166129
[TBL] [Abstract][Full Text] [Related]
16. Epitope analysis of human IL-6 receptor gp80 molecule with monoclonal antibodies.
Liautard J; Gaillard JP; Mani JC; Montero-Julian F; Duperray C; Lu ZY; Jourdan M; Klein B; Brailly H; Brochier J
Eur Cytokine Netw; 1994; 5(3):293-300. PubMed ID: 7524715
[TBL] [Abstract][Full Text] [Related]
17. Murine anti-human IL-6 monoclonal antibody prolongs the half-life in circulating blood and thus prolongs the bioactivity of human IL-6 in mice.
Mihara M; Koishihara Y; Fukui H; Yasukawa K; Ohsugi Y
Immunology; 1991 Sep; 74(1):55-9. PubMed ID: 1718855
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of humanized anti-interleukin-6 receptor antibody: antitumor activity in xenograft model of multiple myeloma.
Tsunenari T; Akamatsu K; Kaiho S; Sato K; Tsuchiya M; Koishihara Y; Kishimoto T; Ohsugi Y
Anticancer Res; 1996; 16(5A):2537-44. PubMed ID: 8917348
[TBL] [Abstract][Full Text] [Related]
19. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
20. Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab).
Mattes MJ; Sharkey RM; Karacay H; Czuczman MS; Goldenberg DM
Clin Cancer Res; 2008 Oct; 14(19):6154-60. PubMed ID: 18829494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
